Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


loader
  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Apleway

    Read More

    Apleway (tofogliflozin; Chugai) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

    November 7, 2017
    Find out more
  • Aplidin

    Read More

    Aplidin is an intravenous, marine-originated cyclic depsipeptide antitumor agent. The drug, which is

    currently synthesized chemically, was originally isolated from the marine tunicate Aplidium albicans

    (Cuadrado et al., 2003; PharmaMar, 2014).

    September 4, 2014
    Find out more
  • Aptiom

    Read More

    Aptiom is a once-daily oral drug containing eslicarbazepine acetate, a third-generation member of the commonly prescribed first-line dibenzazepine family of anti-epileptic drugs (AEDs), including carbamazepine (first-generation) and oxcarbazepine (second-generation).

    May 23, 2017
    Find out more
  • Aramchol

    Read More

    Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the liver enzyme stearoyl-CoA desaturase 1 inhibitor (SCD1), and as a result fatty acid synthesis is reduced while fatty acid oxidation is increased. Additionally, Aramchol has hypocholesterolemic effects due to the upregulation of ATP-binding cassette transporter 1 (ABCA1). Ultimately, Aramchol causes incomplete SCD inhibition while also being anti-atherogenic.

    July 22, 2019
    Find out more
  • Aranesp

    Read More

    Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia.

    January 11, 2018
    Find out more
  • Arcapta

    Arcapta

    Read More

    Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

    July 31, 2018
    Find out more
  • Argentina Healthcare System Overview

    $2,995.00

    With a growing economy and 40 million inhabitants, Argentina is one of the most important emerging market destinations in South America.

    November 3, 2016
    Find out more
  • Argentina Regulatory Issues

    $2,995.00

    With a growing economy and 40 million inhabitants, Argentina is one of the most important emerging market destinations in South America.

    November 2, 2016
    Find out more
  • Aricept

    Read More

    Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
    Alzheimer’s disease for more than a decade.

    September 2, 2016
    Find out more
  • arikayce report

    Arikayce

    Read More

    Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.

    September 3, 2018
    Find out more
  • Aristada

    Read More

    Aristada (aripiprazole lauroxil; Alkermes) is a long-acting injectable formulation of the atypical antipsychotic aripiprazole. It was developed by Alkermes using its proprietary LinkeRx technology, which allows the gradual release of aripiprazole molecules and lowers the drug’s frequency of administration.

    March 19, 2018
    Find out more
  • Aromatase Resistance and Palbociclib for Breast Cancer

    $89.00

    These pathways can be targeted either at the cell surface receptor

    level or their downstream signaling cascades. Currently, everolimus in combination with

    exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

    HDAC inhibitors have also shown promising results For innate resistance, the combination of

    fulvestrant and AI in the front line setting represents a new treatment option, particularly for

    patients who present with de novo metastatic disease.

    April 1, 2014
    Find out more
  • Arthroscopy Products and Sports Medicine Fixation Implants (2021)

    $4,750.00

    This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft tissue fixation implants for the US, five major EU markets, Japan, and the rest of the world.

    March 18, 2021
    Find out more
  • arzerra report

    Arzerra

    Read More

    Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane.

    January 31, 2019
    Find out more
  • Asciminib

    Read More

    Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia.

    December 7, 2017
    Find out more
  • Asia-Pacific Disease Incidence and Prevalence

    $5,250.00

    The Asia-Pacific (APAC) region is a part of the world which includes several developing and developed countries. Countries covered in this report include Australia, China, India, Japan, Malaysia, South Korea, Thailand, and Vietnam.

    January 1, 2016
    Find out more
  • Asia-Pacific: Surgical Procedure Volumes

    $5,250.00

    This report examines the healthcare trends in Asia-Pacific countries (Japan, China, South Korea, India, Thailand, Vietnam, Malaysia and Australia), as well as analyzes and forecasts (toward 2019).

    September 1, 2015
    Find out more
  • aspirin

    Aspirin

    Read More

    Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.

    July 2, 2018
    Find out more
  • Asthma and COPD KOL Interview

    $599.00

    KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

    February 29, 2016
    Find out more
  • Asthma Pricing, Reimbursement, and Access

    $2,995.00

    The next wave of key therapies in asthma includes biologics, with interleukin (IL)-5 inhibitors first to reach the market.

    October 17, 2016
    Find out more
  • ATIR101

    Read More

    ATIR101 is an immunotherapeutic delivered as an adjunctive therapy for patients receiving HSCT.

    July 6, 2017
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview

    Atopic Dermatitis and Psoriasis KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

    Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, South

    Atopic Dermatitis and Psoriasis KOL Interview – US, South

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Atrasentan

    Read More

    Atrasentan’s Phase III trial is unique including an enrichment period to select responders and those who tolerate the drug for randomization.

    February 2, 2018
    Find out more
  • Atripla

    Read More

    Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

    June 28, 2019
    Find out more
  • Aubagio

    Read More

    Aubagio is the major active metabolite of Arava (leflunomide), Sanofi’s oral treatment for rheumatoid arthritis, and is a dihydroorotate dehydrogenase (DHODH) inhibitor.

    November 24, 2017
    Find out more
  • Aurora-GT

    Read More

    United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)

    October 29, 2018
    Find out more
  • Auryxia

    Read More

    Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease.

    January 11, 2018
    Find out more
  • avastin report

    Avastin

    Read More

    Avastin (bevacizumab; Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

    February 26, 2020
    Find out more
  • Avonex

    Read More

    Avonex is a biological therapy derived from the interferon family, and Biogen’s leading drug for treating relapsing-remitting multiple sclerosis (RRMS).

    November 24, 2017
    Find out more
  • Azeliragon

    Read More

    Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).

    September 2, 2016
    Find out more
  • Azilect

    Read More

    Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.

    June 21, 2018
    Find out more
  • balixafortide

    Read More

    Balixafortide (Polyphor) is a synthetic cyclopeptide derived from polyphemusin that inhibits C-X-C motif chemokine receptor 4 (CXCR4), a G-protein coupled receptor that exclusively binds to its ligand, stromal cell-derived factor-1 (SDF-1).

    February 26, 2020
    Find out more
  • banzel report

    Banzel

    Read More

    Eisai’s Banzel is an oral sodium channel modulator which is structurally different from currently approved anticonvulsants on account of its triazole derivative structure. The drug’s sole approved indication is the adjunctive treatment of seizures…

    May 23, 2017
    Find out more
  • bardoxolone methyl

    Read More

    Bardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary arterial hypertension.

    October 29, 2018
    Find out more
  • baricitinib

    Read More

    Baricitinib is an oral reversible inhibitor of Janus kinase-1 (JAK1) and JAK2 – that is JAK3-sparing – under co-development by Incyte and Eli Lilly. It is currently in development for the treatment of inflammatory conditions including…

    October 4, 2016
    Find out more
  • Bavencio

    Read More

    Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.

    March 6, 2019
    Find out more
  • Bax 817

    Read More

    BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…

    March 14, 2016
    Find out more
  • Bay 94-9027

    Read More

    BAY 94-9027 (Bayer) is a long-acting recombinant factor VIII (rfVIII) product under development for the treatment of hemophilia A.

    May 4, 2018
    Find out more
  • bb2121

    Read More

    Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.

    August 9, 2018
    Find out more
  • bempedoic acid franchise

    Bempedoic Acid Franchise

    Read More

    Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.

    November 20, 2019
    Find out more
  • BeneFix

    Read More

    BeneFIX (Pfizer) is an recombinant factor IX (rfIX) therapy indicated for the control and prevention of bleeding in hemophilia B.

    May 4, 2018
    Find out more
  • Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market

    $4,750.00

    Symptomatic benign prostatic hyperplasia (BPH) and prostatitis affect more than 100 million men worldwide, lowering quality of life with painful symptoms that can be difficult to manage.

    April 20, 2017
    Find out more
  • Beraprost 314d

    Read More

    Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…

    June 19, 2015
    Find out more
Page 3 of 29
Page 3 of 29‹12345›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top